Please login to the form below

Not currently logged in
Email:
Password:

Sanofi posts positive data for MS drug Aubagio

Phase III study shows drug slows brain volume loss
Sanofi

Sanofi's Aubagio has significantly slowed brain volume loss over two years in people with relapsing MS in a new analysis of a phase III trial.

Magnetic resonance imaging (MRI) was used in the trial, called TEMSO, to assess changes in brain volume from baseline in patients with Aubagio (teriflunomide) 14mg, 7mg or placebo.

The results showed that after 24 months median reduction in brain volume was 0.9% for Aubagio 14mg, 0.94% for 7mg and 1.29% for placebo.

Bill Sibold, head of Sanofi's Genzyme MS unit, said: “Control or prevention of brain atrophy is an important target for MS treatment.

“These results show the reduction in brain atrophy over two years add to the growing body of data for Aubagio. We remain committed to furthering the understanding of Aubagio and the potential benefits it could deliver to relapsing MS patients.”

The FDA approved Aubagio for MS in 2012, and although it was not considered to be as effective as rival treatments like Novartis' Gilenya (fingolimod), which achieved sales of $494m in 2011, it has a significantly favourable side effect profile that places it fairly well within the market.

Additionally, competition also comes from Biogen Idec's Tecfidera (dimethyl fumarate), which managed to sell three times more in 8 months than Aubagio managed in a full year.

Brain atrophy is the result of the destructive pathological processes that occur in MS. It is seen from the earliest stages of disease and leads to irreversible neurological and cognitive impairment.

A recent report from GlobalData states that the value of the multiple sclerosis market will rise from $17.2bn in 2014 to approximately $20bn by 2024. 

The market is expected to plateau from 2018 to 2020, but steady growth will resume from 2020 onwards as additional pipeline products become available. 

Article by
Nikhil Patel

7th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics